Upgrade to SI Premium - Free Trial

Sleep Number Announces Fourth Quarter and Full Year 2025 Results

March 12, 2026 7:00 AM

Reports FY2025 Net Sales of $1.4 Billion, Exceeding Adjusted EBITDA Guidance

Realized $185 Million of Annualized Cost Savings

Launches New Products as the Next Phase of Turnaround Strategy to Return to Profitable Growth

MINNEAPOLIS--(BUSINESS WIRE)-- Sleep Number Corporation (Nasdaq: SNBR) today reported results for fourth quarter and the year ended January 3, 2026.

Linda Findley, President and CEO, commented, "Sleep Number exceeded 2025 guidance provided on our last earnings call. We are still in full turnaround mode and made significant progress against our new product and marketing strategies while continuing to reduce costs. For the full year 2025, pro-forma adjusted EBITDA margin was approximately 9% and anticipate double-digit adjusted EBITDA growth in 2026 as we continue to execute on our strategy.

"The launch of our ComfortMode bed in January exceeded our expectations and is outselling plan by 3.5 times, with stronger margins than the beds it replaces. The rest of the new product line, available this month, is all built on the same consumer research highlighting comfort and value, and we anticipate similar strength from the new beds, as the supporting marketing is also performing well.

"Even with the strength of our product and marketing strategies, the negative industry impact at the start of the year plus the clearance of our existing products had an outsized impact on our liquidity. We are implementing a plan to address our liquidity and capital strategy as we move towards topline growth in the second half of the year."

Fourth Quarter Overview (all comparisons year-over-year unless otherwise noted)

Full Year Overview (all comparisons year-over-year unless otherwise noted)

Cash Flows and Liquidity Review (all comparisons year-over-year unless otherwise noted)

Additional Business Highlights

Sleep Number is executing a turnaround strategy centered on product, marketing and distribution with ongoing cost savings and operating efficiencies to reignite growth and increase financial resilience. Recent highlights include:

Conference Call Information

Management will host its regularly scheduled conference call to discuss the company’s results at 8:30 a.m. ET (7:30 a.m. CT; 5:30 a.m. PT) today. To access the webcast, please visit the investor relations area of the Sleep Number website at https://ir.sleepnumber.com. The webcast replay will remain available for approximately 60 days.

About Sleep Number Corporation

Sleep Number is the leader in personalized sleep wellness. Its mattresses are designed to evolve with each sleeper to help them feel and perform their best. With adjustable firmness, pressure-relieving support and temperature balancing comfort built into every mattress, Sleep Number® beds adapt to customers’ changing needs, night after night, year after year.

Backed by almost 40 years of innovation, 1,000+ patents and patents pending, and billions of hours of sleep data, Sleep Number has helped more than 16 million people achieve their best sleep. The fully integrated model ensures quality, durability, and care at every step—from design and craftsmanship to delivery and long-term support.

Sleep Number products are awarded the industry's top recognitions, including ranked #1 in customer satisfaction for mattresses purchased in-store and online, and #1 in comfort, by J.D. Power. In addition, the company is the Official Sleep + Wellness Partner of the NFL, marking a relationship that leverages player health data, team partnerships, and league-wide initiatives to amplify brand awareness and drive consumer engagement.

Sleep Number mattresses, bases, bedding, and furniture are available exclusively at its 600 stores nationwide and online. To learn more, visit SleepNumber.com or a store near you.

Forward-looking Statements

Statements used in this news release relating to future plans, events, financial results or performance, such as the statements that: the company is launching new products as the next phase of its turnaround strategy to return to profitable growth; it anticipates double digit increase to adjusted EBITDA in 2026; it anticipates strong sales and margins from the new product line launching this month; it is implementing a plan to address liquidity and capital strategy as it moves towards topline growth in the second half of 2026; it is executing a turnaround strategy centered on product, marketing and distribution with ongoing cost savings and operating efficiencies to reignite growth and increase financial resilience; it is implementing $50 million of annualized fixed costs savings in 2026; and it is working with Guggenheim Securities to address the company's amended credit facility and improve its liquidity, balance sheet and flexibility are forward-looking statements subject to certain risks and uncertainties which could cause the company’s results to differ materially. The most important risks and uncertainties are described in the company’s filings with the Securities and Exchange Commission, including in Item 1A of the company’s Annual Report on Form 10-K and other periodic reports. Forward-looking statements speak only as of the date they are made, and the company does not undertake any obligation to update any forward-looking statement.

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Consolidated Statements of Operations

(unaudited – in thousands, except per share amounts)

Fourteen Weeks Ended

Thirteen Weeks Ended

January 3,
2026

% of

Net Sales

December 28,
2024

% of

Net Sales

Net sales

$

347,385

100.0

%

$

376,817

100.0

%

Cost of sales

154,103

44.4

%

151,236

40.1

%

Gross profit

193,282

55.6

%

225,581

59.9

%

Operating expenses:

Sales and marketing

161,238

46.4

%

170,232

45.2

%

General and administrative

30,654

8.8

%

38,234

10.1

%

Research and development

6,291

1.8

%

10,653

2.8

%

Restructuring costs

3,151

0.9

%

3,684

1.0

%

Total operating expenses

201,334

58.0

%

222,803

59.1

%

Operating (loss) income

(8,052

)

(2.3

%)

2,778

0.7

%

Interest expense, net

13,880

4.0

%

11,742

3.1

%

Loss before income taxes

(21,932

)

(6.3

%)

(8,964

)

(2.4

%)

Income tax expense (benefit)

36,578

10.5

%

(4,299

)

(1.1

%)

Net loss

$

(58,510

)

(16.8

%)

$

(4,665

)

(1.2

%)

Net loss per share – basic and diluted

$

(2.55

)

$

(0.21

)

Reconciliation of weighted-average shares outstanding:

Basic weighted-average shares outstanding

22,952

22,659

Dilutive effect of stock-based awards

Diluted weighted-average shares outstanding

22,952

22,659

For the fourteen weeks ended January 3, 2026 and the thirteen weeks ended December 28, 2024, potentially dilutive stock-based awards have been excluded from the calculation of diluted weighted-average shares outstanding, as their inclusion would have had an anti-dilutive effect on our net loss per diluted share.

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Consolidated Statements of Operations

(unaudited – in thousands, except per share amounts)

Fifty-Three Weeks Ended

Fifty-Two Weeks Ended

January 3,
2026

% of

Net Sales

December 28,
2024

% of

Net Sales

Net sales

$

1,411,450

100.0

%

$

1,682,296

100.0

%

Cost of sales

578,499

41.0

%

679,523

40.4

%

Gross profit

832,951

59.0

%

1,002,773

59.6

%

Operating expenses:

Sales and marketing

664,235

47.1

%

766,624

45.6

%

General and administrative

130,669

9.3

%

149,956

8.9

%

Research and development

33,942

2.4

%

45,255

2.7

%

Restructuring costs

50,697

3.6

%

18,066

1.1

%

Total operating expenses

879,543

62.3

%

979,901

58.2

%

Operating (loss) income

(46,592

)

(3.3

%)

22,872

1.4

%

Interest expense, net

49,382

3.5

%

48,368

2.9

%

Loss before income taxes

(95,974

)

(6.8

%)

(25,496

)

(1.5

%)

Income tax expense (benefit)

35,984

2.5

%

(5,162

)

(0.3

%)

Net loss

$

(131,958

)

(9.3

%)

$

(20,334

)

(1.2

%)

Net loss per share – basic and diluted

$

(5.77

)

$

(0.90

)

Reconciliation of weighted-average shares outstanding:

Basic weighted-average shares outstanding

22,883

22,606

Dilutive effect of stock-based awards

Diluted weighted-average shares outstanding

22,883

22,606

For the fifty-three weeks ended January 3, 2026 and the fifty-two weeks ended December 28, 2024, potentially dilutive stock-based awards have been excluded from the calculation of diluted weighted-average shares outstanding, as their inclusion would have had an anti-dilutive effect on our net loss per diluted share.

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Consolidated Balance Sheets

(unaudited – in thousands, except per share amounts)

subject to reclassification

January 3,
2026

December 28,
2024

Assets

Current assets:

Cash and cash equivalents

$

1,693

$

1,950

Accounts receivable, net of allowances of $694 and $1,113, respectively

15,502

17,516

Inventories

82,233

103,152

Prepaid expenses

13,656

14,568

Other current assets

36,873

44,098

Total current assets

149,957

181,284

Non-current assets:

Property and equipment, net

86,528

129,574

Operating lease right-of-use assets

311,723

356,641

Goodwill and intangible assets, net

66,186

66,412

Deferred income taxes

399

33,575

Other non-current assets

65,267

93,324

Total assets

$

680,060

$

860,810

Liabilities and Shareholders’ Deficit

Current liabilities:

Borrowings under revolving credit facility

$

588,200

$

546,600

Accounts payable

117,977

107,619

Customer prepayments

39,527

46,933

Accrued sales returns

12,817

19,092

Compensation and benefits

14,975

31,038

Taxes and withholding

11,429

18,619

Operating lease liabilities

81,191

82,307

Other current liabilities

46,430

55,804

Total current liabilities

912,546

908,012

Non-current liabilities:

Operating lease liabilities

273,111

307,201

Other non-current liabilities

72,878

97,183

Total non-current liabilities

345,989

404,384

Total liabilities

1,258,535

1,312,396

Shareholders’ deficit:

Undesignated preferred stock; 5,000 shares authorized, no shares issued and outstanding

Common stock, $0.01 par value; 142,500 shares authorized, 22,860 and 22,388 shares issued and outstanding, respectively

229

224

Additional paid-in capital

32,454

27,390

Accumulated deficit

(611,158

)

(479,200

)

Total shareholders’ deficit

(578,475

)

(451,586

)

Total liabilities and shareholders’ deficit

$

680,060

$

860,810

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(unaudited – in thousands)

subject to reclassification

Fifty-Three Weeks Ended

Fifty-Two Weeks Ended

January 3,
2026

December 28,
2024

Cash flows from operating activities:

Net loss

$

(131,958

)

$

(20,334

)

Adjustments to reconcile net loss to net cash (used in) provided by

operating activities:

Depreciation and amortization

55,608

66,351

Stock-based compensation

6,282

11,444

Inventory obsolescence write off

9,565

Loss on impairment of strategic investment asset

16,225

Loss on disposal and impairment of leased assets

20,319

4,315

Deferred income taxes

33,176

(13,322

)

Changes in operating assets and liabilities:

Accounts receivable

2,014

9,343

Inventories

11,354

12,281

Income taxes

(4,378

)

3,987

Prepaid expenses and other assets

9,889

(10,867

)

Accounts payable

22,673

(15,910

)

Customer prepayments

(7,406

)

(2,210

)

Accrued compensation and benefits

(16,113

)

2,755

Other taxes and withholding

(2,812

)

(2,502

)

Other accruals and liabilities

(27,721

)

(18,188

)

Net cash (used in) provided by operating activities

(3,283

)

27,143

Cash flows from investing activities:

Purchases of property and equipment

(14,407

)

(23,505

)

Proceeds from sales of property and equipment

156

Issuance of notes receivable

(2,942

)

Payment to secure contractual rights

(3,280

)

Net cash used in investing activities

(17,687

)

(26,291

)

Cash flows from financing activities:

Net increase (decrease) in short-term borrowings

28,068

(673

)

Repurchases of common stock

(1,213

)

(768

)

Debt issuance costs

(6,142

)

Net cash provided by (used in) financing activities

20,713

(1,441

)

Net decrease in cash and cash equivalents

(257

)

(589

)

Cash and cash equivalents, at beginning of period

1,950

2,539

Cash and cash equivalents, at end of period

$

1,693

$

1,950

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Supplemental Financial Information

(unaudited)

Fourteen Weeks Ended

Thirteen Weeks Ended

Fifty-Three Weeks Ended

Fifty-Two Weeks Ended

January 3,
2026

December 28,
2024

January 3,
2026

December 28,
2024

Percent of sales:

Retail stores

86.6

%

86.6

%

87.6

%

87.6

%

Online, phone, chat and other

13.4

%

13.4

%

12.4

%

12.4

%

Total Company

100.0

%

100.0

%

100.0

%

100.0

%

Sales change rates:

Retail comparable-store sales4

(15

%)

(9

%)

(17

%)

(9

%)

Online, phone and chat4

(15

%)

(17

%)

(17

%)

(17

%)

Total Retail comparable sales change4

(15

%)

(10

%)

(17

%)

(10

%)

Net opened/closed stores and other

7

%

(2

%)

1

%

(1

%)

Total Company

(8

%)

(12

%)

(16

%)

(11

%)

Stores open:

Beginning of period

611

643

640

672

Opened

1

1

6

12

Closed

(12

)

(4

)

(46

)

(44

)

End of period

600

640

600

640

Other metrics:

Average sales per store ($ in 000's)1,4

$

1,946

$

2,601

Average sales per square foot1,4

$

629

$

841

Stores > $2 million net sales2,4

32

%

57

%

Stores > $3 million net sales2,4

8

%

18

%

Average revenue per smart bed unit3

$

6,393

$

5,959

$

6,060

$

5,818

1

Trailing twelve months Total Retail comparable sales per store open at least one year.

2

Trailing twelve months for stores open at least one year (excludes online, phone and chat sales).

3

Represents Total Retail (stores, online, phone and chat) net sales divided by Total Retail smart bed units.

4

Fiscal 2025 included 53 weeks, as compared to 52 weeks in fiscal 2024. The additional week in 2025 was in the fiscal fourth quarter. Total Retail comparable sales have been adjusted to remove the estimated impact of the additional week on the three and twelve months ended January 3, 2026.

SLEEP NUMBER CORPORATION AND SUBSIDIARIES
Earnings before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA)
(in thousands)

We define earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) as net loss plus: income tax expense (benefit), interest expense, depreciation and amortization, stock-based compensation, restructuring costs, other non-recurring items, and asset impairments. Management believes Adjusted EBITDA is a useful indicator of our financial performance and our ability to generate cash from operating activities. Our definition of Adjusted EBITDA may not be comparable to similarly titled definitions used by other companies. The table below reconciles Adjusted EBITDA, which is a non-GAAP financial measure, to the comparable GAAP financial measure:

Three Months Ended

Trailing Twelve Months Ended

January 3,
2026

December 28,
2024

January 3,
2026

December 28,
2024

Net loss

$

(58,510

)

$

(4,665

)

$

(131,958

)

$

(20,334

)

Income tax expense (benefit)

36,578

(4,299

)

35,984

(5,162

)

Interest expense

13,880

11,742

49,382

48,368

Depreciation and amortization

12,091

15,628

53,169

64,979

Stock-based compensation

1,570

1,903

6,282

11,444

Restructuring costs1

3,151

3,684

50,697

18,066

Other non-recurring items2

10,643

998

14,699

998

Asset impairments

1,220

1,220

Adjusted EBITDA

$

19,403

$

26,211

$

78,255

$

119,579

1

Represents costs related to business restructuring actions.

2

Other non-recurring items includes the following:

Three Months Ended

Trailing Twelve Months Ended

January 3,
2026

December 28,
2024

January 3,
2026

December 28,
2024

Inventory obsolescence write off

$

9,565

$

$

9,565

$

CEO transition costs

450

224

1,584

224

Debt issuance cost write off

1,596

Proxy contest costs

774

1,148

774

CFO search costs

164

340

Legal and consulting costs

464

466

Other non-recurring items

$

10,643

$

998

$

14,699

$

998

Free Cash Flow

(in thousands)

Three Months Ended

Trailing Twelve Months Ended

January 3,
2026

December 28,
2024

January 3,
2026

December 28,
2024

Net cash provided by (used in) operating activities

$

1,876

$

(23,681

)

$

(3,283

)

$

27,143

Subtract: Purchases of property and equipment

2,519

6,287

14,407

23,505

Free cash flow

$

(643

)

$

(29,968

)

$

(17,690

)

$

3,638

Note - Our Adjusted EBITDA and Free Cash Flow are considered non-GAAP financial measures and are not in accordance with, or preferable to, "as reported," or GAAP financial data. However, we are providing this information as we believe it facilitates analysis of the Company's financial performance by investors and financial analysts.

GAAP - generally accepted accounting principles in the U.S.

SLEEP NUMBER CORPORATION AND SUBSIDIARIES

Reconciliation of GAAP to Non-GAAP Financial Measures

(in thousands)

Three Months Ended

Trailing Twelve Months Ended

January 3,
2026

December 28,
2024

January 3,
2026

December 28,
2024

Operating expenses

$

201,334

$

222,803

$

879,543

$

979,901

Subtract: Restructuring costs

3,151

3,684

50,697

18,066

Subtract: Asset impairments

1,220

1,220

Subtract: Other non-recurring items1

1,078

998

5,134

998

Non-GAAP operating expenses

$

197,105

$

216,901

$

823,712

$

959,617

Operating expense reduction versus prior period, excluding restructuring costs and non-recurring items

$

19,796

$

135,905

1

Excludes inventory obsolescence write off of $9.6 million, which is included in the cost of sales line on the statement of operations.

Three Months Ended

Trailing Twelve Months Ended

January 3,
2026

December 28,
2024

January 3,
2026

December 28,
2024

Gross profit

$

193,282

$

225,581

$

832,951

$

1,002,773

Gross profit margin

55.6

%

59.9

%

59.0

%

59.6

%

Add: Inventory obsolescence write off

9,565

9,565

Non-GAAP gross profit

$

202,847

$

225,581

$

842,516

$

1,002,773

Non-GAAP gross profit margin

58.4

%

59.9

%

59.7

%

59.6

%

Trailing Twelve Months Ended

January 3,
2026

Adjusted EBITDA

$

78,255

Proforma annualized cost reductions1

50,000

Proforma adjusted EBITDA

128,255

Net sales

1,411,450

Proforma adjusted EBITDA margin

9.1

%

1

Represents annualized impact of cost reductions over the future trailing twelve months the Company has executed.

Note - Our Non-GAAP Operating Expenses, Non-GAAP Gross Profit, Non-GAAP Gross Profit Margin, and Proforma Adjusted EBITDA measures are considered non-GAAP financial measures and are not in accordance with, or preferable to, "as reported," or GAAP financial data. However, we are providing this information as we believe it facilitates analysis of the Company's financial performance by investors and financial analysts.

GAAP - generally accepted accounting principles in the U.S.

SLEEP NUMBER CORPORATION AND SUBSIDIARIES

Calculation of Net Leverage Ratio under Revolving Credit Facility

(in thousands)

Trailing Twelve Months Ended

January 3,
2026

December 28,
2024

Borrowings under revolving credit facility

$

588,200

$

546,600

Outstanding letters of credit

8,800

7,147

Finance lease obligations

159

241

Consolidated funded indebtedness

$

597,159

$

553,988

Operating lease liabilities1

354,302

389,508

Total debt including operating lease liabilities (a)

$

951,461

$

943,496

Adjusted EBITDA (see above)

$

78,255

$

119,579

Consolidated rent expense

104,983

107,105

Proforma annualized cost reductions2

50,000

Consolidated EBITDAR (b)

$

233,238

$

226,684

Net Leverage Ratio under revolving credit facility (a divided by b)

4.1 to 1.0

4.2 to 1.0

1

Reflects operating lease liabilities included in our financial statements under ASC 842.

2

Represents annualized impact of cost reductions over the future trailing twelve months the Company has executed.

Note - Our Net Leverage Ratio under Revolving Credit Facility, Adjusted EBITDA and EBITDAR calculations are considered non-GAAP financial measures and are not in accordance with, or preferable to, "as reported," or GAAP financial data. However, we are providing this information as we believe it facilitates analysis of the Company's financial performance by investors and financial analysts.

GAAP - generally accepted accounting principles in the U.S.

SLEEP NUMBER CORPORATION AND SUBSIDIARIES
Calculation of Return on Invested Capital (Adjusted ROIC)
(in thousands)

Adjusted ROIC is a financial measure we use to determine how efficiently we deploy our capital. It quantifies the return we earn on our adjusted invested capital. Management believes Adjusted ROIC is also a useful metric for investors and financial analysts. We compute Adjusted ROIC as outlined below. Our definition and calculation of Adjusted ROIC may not be comparable to similarly titled definitions and calculations used by other companies. The tables below reconcile adjusted net operating profit after taxes (Adjusted NOPAT) and total adjusted invested capital, which are non-GAAP financial measures, to the comparable GAAP financial measures:

Trailing Twelve Months Ended

January 3,
2026

December 28,
2024

Adjusted net operating profit after taxes (Adjusted NOPAT)

Operating income

$

(46,592

)

$

22,872

Add: Operating lease interest1

24,346

26,775

Less: Income taxes2

4,495

(11,907

)

Adjusted NOPAT

$

(17,751

)

$

37,740

Average adjusted invested capital

Total deficit

$

(578,475

)

$

(451,586

)

Add: Long-term debt3

588,359

546,841

Add: Operating lease liabilities4

354,302

389,508

Total adjusted invested capital at end of period

$

364,186

$

484,763

Average adjusted invested capital5

$

439,902

$

497,972

Adjusted ROIC6

(4.0

%)

7.6

%

1

Represents the interest expense component of lease expense included in our financial statements under ASC 842, Leases.

2

Reflects annual effective income tax rates, before discrete adjustments, of 20.2% and 24.0% for January 3, 2026 and December 28, 2024, respectively.

3

Long-term debt includes existing finance lease liabilities.

4

Reflects operating lease liabilities included in our financial statements under ASC 842.

5

Average adjusted invested capital represents the average of the last five fiscal quarters' ending adjusted invested capital balances.

6

Adjusted ROIC equals Adjusted NOPAT divided by average adjusted invested capital.

Note - The Company's Adjusted ROIC calculation and data are considered non-GAAP financial measures and are not in accordance with, or preferable to, "as reported," or GAAP financial data. However, we are providing this information as we believe it facilitates analysis of the Company's financial performance by investors and financial analysts.

GAAP - generally accepted accounting principles in the U.S.

Investor Contact: [email protected]

Media Contact: Muriel Lussier, [email protected]

Source: Sleep Number Corporation

Categories

Business Wire Press Releases